TSE:4503Pharmaceuticals
Assessing Astellas Pharma (TSE:4503) Valuation After Its Strong 1-Year Share Price Rally
Astellas Pharma (TSE:4503) has quietly outperformed the broader Japanese market over the past year, gaining about 43% as investors warm to its oncology pipeline, steady cash generation, and improving long term return profile.
See our latest analysis for Astellas Pharma.
That momentum has not come out of nowhere, with a 90 day share price return of 26.7% and a 1 year total shareholder return of about 43% pointing to steadily improving sentiment rather than a brief spike.
If Astellas recent run...